SCHEMBL721277

SCHEMBL721277

CCCCCC1=NS(=O)(=O)c2ccc(Cl)cc2N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
HTR1A P08908 1/20 0.46
ALDH1A1 P00352 6/20 0.46
LMNA P02545 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
THRB P10828 3/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
TSHR P16473 2/20 0.46
CYP1A2 P05177 1/20 0.46
ABCC8 Q09428 1/20 0.46
KCNJ11 Q14654 1/20 0.46
MAPT P10636 3/20 0.43
TP53 P04637 2/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NR1I2 O75469 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719010 0.96 NPC1 (0.47) NPC1HTR1AALDH1A1LMNASMN1; SMN2
SCHEMBL7944207 0.77 ALDH1A1 (0.42) HTR1AALDH1A1LMNASMN1; SMN2THRB
SCHEMBL7944026 0.77 ALDH1A1 (0.42) HTR1AALDH1A1LMNASMN1; SMN2THRB
SCHEMBL7951206 0.76 CYP1A2 (0.44) NPC1HTR1AALDH1A1LMNASMN1; SMN2
SCHEMBL720640 0.74 ALDH1A1 (0.66) NPC1HTR1AALDH1A1LMNASMN1; SMN2
SCHEMBL8492228 0.74 ALDH1A1 (0.50) HTR1AALDH1A1LMNASMN1; SMN2THRB
SCHEMBL7950905 0.74 ABCC8 (0.56) HTR1AALDH1A1LMNASMN1; SMN2THRB
SCHEMBL7950736 0.74 CYP1A2 (0.47) HTR1AALDH1A1LMNASMN1; SMN2THRB
SCHEMBL10522003 0.72 CA2 (0.40) ABCC8KCNJ11MEN1KMT2ASIRT1
SCHEMBL720597 0.72 MEN1 (0.36) NPC1HTR1AALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053172-A1 USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS COOPERATIEVE MIRZORG U.A. 2012-03-01 US disclosed
US-20100234362-A1 USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL COOPERATIEVE MIRZORG U.A. (NL) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053172-A1 USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS GPR119, KCNJ1, GLP1R NPC1 797/4885HTR1A 1765/4885ALDH1A1 1266/4885
US-20100234362-A1 USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL KCNN4, KCNN1, GPR119 NPC1 932/4885HTR1A 1879/4885ALDH1A1 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.